Therapeutic Plasmapheresis (Apheresis) Should Be Initiated Immediately
For this 75-year-old woman with Waldenström macroglobulinemia presenting with symptomatic hyperviscosity syndrome (headache, intermittent confusion, fever, IgM spike), therapeutic plasmapheresis is the immediate first-line intervention that must be performed NOW, followed by systemic chemotherapy. The correct answer is #2: Therapeutic apheresis.
Rationale for Immediate Plasmapheresis
The patient has clear symptoms of hyperviscosity syndrome:
- Neurological symptoms (headache, intermittent confusion)
- Elevated serum protein (6.9 g/dL) with IgM monoclonal spike
- Bulky lymphadenopathy (enlarged mediastinal and para-aortic nodes)
Plasmapheresis provides immediate symptomatic relief and is mandatory before initiating systemic therapy 1, 2. A 3-4 liter plasma exchange will lower plasma IgM levels by approximately 60-75%, and serum viscosity by at least 50% 1. This is a temporizing measure that provides rapid relief while systemic therapy is being organized 3.
Why the Other Options Are Incorrect
Corticosteroids Alone (#1)
Corticosteroids are NOT recommended as monotherapy for WM with hyperviscosity. They are only used as part of combination regimens (DRC, BDR) but never alone for this presentation 1, 2.
Red Blood Cell Transfusion (#3)
Transfusion is contraindicated in hyperviscosity syndrome - it would worsen the hyperviscosity by increasing blood volume and viscosity, potentially precipitating cardiovascular complications or worsening neurological symptoms. The patient's symptoms are from hyperviscosity, not anemia per se.
Weight-Based Infusion/Intravenous Infusion (#4)
This option is too vague, but if referring to rituximab or chemotherapy alone: Rituximab is contraindicated as initial therapy in patients with high IgM levels or hyperviscosity without preemptive plasmapheresis 2, 3, 4. Rituximab can cause an IgM flare that worsens hyperviscosity symptoms 5, 4.
Complete Treatment Algorithm
Step 1: Immediate Plasmapheresis (NOW)
- Perform 3-4 liter plasma exchange
- May require multiple exchanges over consecutive days 6, 7
- Continue until symptoms resolve and IgM levels decrease
Step 2: Systemic Therapy (Immediately After Plasmapheresis)
Given this patient's presentation with:
- Symptomatic hyperviscosity
- Bulky adenopathy
- Profound symptoms requiring immediate disease control
Preferred regimen: Bendamustine + Rituximab (BR) for 4-6 cycles 2, 3
- Provides rapid disease control for bulky disease
- High response rates (>80%)
- Well-tolerated in elderly patients
Alternative regimen: Bortezomib-based therapy (BDR or VR) 2
- Particularly effective for rapid IgM reduction
- Preferred when expeditious disease control needed
- Caution: Avoid if patient has pre-existing neuropathy
DRC regimen (Dexamethasone/Rituximab/Cyclophosphamide) 1
- Appropriate for lower disease burden
- Less aggressive option for frail patients
- This patient's bulky disease makes BR or bortezomib-based therapy more appropriate
Step 3: Supportive Care
- Herpes zoster prophylaxis with proteasome inhibitors 8, 3
- Monitor IgG levels during therapy 8
- HBV screening and prophylaxis if indicated 8
Critical Pitfalls to Avoid
- Never transfuse RBCs in active hyperviscosity - worsens symptoms
- Never start rituximab without plasmapheresis first in high IgM states - causes IgM flare 2, 3, 4
- Never delay plasmapheresis - hyperviscosity is a medical emergency requiring immediate intervention 2
- Avoid nucleoside analogues (fludarabine) in first-line if patient is transplant-eligible - causes stem cell mobilization difficulties and increased transformation risk 1
Evidence Strength
The recommendation for immediate plasmapheresis in symptomatic hyperviscosity is consistent across all major guidelines:
All guidelines uniformly recommend plasmapheresis as the immediate first intervention for symptomatic hyperviscosity (Grade A/B recommendation, Level III-IV evidence) 1, 2.